Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 4/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 3/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 4/20 | 0.33 |
| ▸ | DRD2 | P14416 | 4/20 | 0.33 |
| ▸ | DRD4 | P21917 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12798246 | 0.87 | ALDH1A1 (0.34) | ALDH1A1POLBHPGDBLMHSD17B10 | |
| SCHEMBL1662379 | 0.82 | RECQL (0.47) | ALDH1A1HPGD | |
| SCHEMBL9894320 | 0.76 | HTR2B (0.38) | HTR2B | |
| SCHEMBL14782547 | 0.76 | HTR2B (0.38) | ALDH1A1POLBHPGDHTR2B | |
| SCHEMBL14574589 | 0.75 | POLB (0.37) | ALDH1A1POLBHPGDBLMHSD17B10 | |
| SCHEMBL1662947 | 0.73 | RBP4 (0.37) | HTR2BDRD2 | |
| SCHEMBL9894217 | 0.73 | HTR2B (0.36) | HTR2BFASN | |
| SCHEMBL6168951 | 0.73 | HTR2B (0.51) | HTR2B | |
| SCHEMBL6166219 | 0.72 | HTR2B (0.49) | ALDH1A1HPGDHSD17B10HTR2BKCNH2 | |
| SCHEMBL6168647 | 0.71 | HTR2B (0.41) | ALDH1A1HPGDHTR2BKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491032-B1 | AKT INHIBITORS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8436002-B2 | AKT inhibitors | ELI LILLY AND COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2491032-A1 | AKT INHIBITORS | Eli Lilly and Company (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20120149684-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011050016-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149684-A1 | AKT INHIBITORS | AKT2, PIK3CA, AKT3 | ALDH1A1 2866/4885POLB 3736/4885HPGD 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.